Last 47 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.01 | — | — | — | — | — | — | 0.90 | — | — | — | — | — | — | — | — | — | — | — | 52.34 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.01 | 2.11 | 0.98 | 0.98 | 0.32 | 0.24 | 0.26 | 0.70 | 0.67 | 0.78 | 1.32 | 0.74 | 1.06 | 20.40 | 2.85 | 34.15 | 45.44 | 33.95 | 44.91 | 16.56 | 43.70 |
| — | +763.4% | +272.0% | +41.2% | -51.9% | -68.7% | -79.9% | -5.3% | -37.2% | -96.2% | -53.9% | -97.8% | -97.7% | -39.9% | -93.7% | +106.2% | +4.0% | -73.6% | -64.4% | -86.4% | +247.9% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 82.77 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 44.35 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | 1.87 | — | — | — | — | — | — | — | — | — | 44.89 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.9% | 96.8% | 96.1% | 95.6% | 95.2% | 97.2% | 95.7% | 95.6% | 96.6% | 96.4% | 94.0% | 95.4% | 97.5% | 96.8% | 96.5% | 94.4% | 97.3% | 97.6% | 97.0% | 99.4% | 98.4% |
| — | -0.5% | +0.5% | +0.0% | -1.5% | +0.9% | +1.8% | +0.3% | -0.8% | -0.5% | -2.6% | +1.0% | +0.2% | -0.8% | -0.5% | -5.0% | -1.2% | +2.8% | +1.1% | +2.5% | +0.5% | |
| Operating Margin | -62.1% | -67.4% | -76.3% | -52.4% | -34.6% | -64.3% | -110.8% | -102.4% | -67.8% | -65.7% | -101.9% | -112.0% | -86.8% | -78.7% | -79.8% | -100.9% | -85.3% | -108.1% | -72.6% | 37.2% | -116.2% |
| — | -4.8% | +31.1% | +48.9% | +49.0% | +2.2% | -8.7% | +8.6% | +21.9% | +16.5% | -27.6% | -11.1% | -1.7% | +27.2% | -10.1% | -371.2% | +26.6% | +50.2% | +67.8% | +135.2% | +47.4% | |
| Net Margin | -134.2% | -200.5% | -63.9% | -299.9% | -75.2% | -98.2% | -78.2% | -100.8% | -82.7% | 55.6% | -112.8% | -124.0% | -95.8% | -86.8% | -88.2% | -114.7% | -100.5% | -123.6% | -86.8% | 30.7% | -137.5% |
| — | -104.1% | +18.3% | -197.6% | +9.0% | -276.6% | +30.7% | +18.7% | +13.7% | +164.0% | -27.9% | -8.1% | +4.6% | +29.8% | -1.5% | -473.9% | +26.9% | +47.8% | +64.8% | +124.8% | +45.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | -143.7% | -55.2% | -18.7% | -99.9% | -32.9% | -32.0% | -16.1% | -17.4% | -15.9% | 11.4% | -16.8% | -16.4% | -12.2% | -10.5% | -10.0% | -13.1% | -14.9% | -17.8% | -13.8% | 13.8% | -19.2% |
| — | -72.4% | -16.2% | -474.2% | -107.2% | -381.7% | +4.4% | -6.1% | -30.8% | +208.7% | -68.3% | -25.5% | +18.4% | +41.3% | +27.8% | -194.4% | +22.3% | +6.6% | +29.3% | +203.7% | -28.6% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | -256.7% | -78.9% | -58.9% | -60.5% | -93.3% | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | -175.2% | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 3.83 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.12 | 0.79 | 1.08 | 1.12 | 1.03 | 0.99 | 1.33 | 1.70 | 3.00 | 3.62 | 3.04 | 3.37 | 4.24 | 4.94 | 5.17 | 5.31 | 3.61 | 3.88 | 4.17 | 3.74 | 3.51 |
| — | -19.7% | -19.1% | -33.9% | -65.7% | -72.7% | -56.2% | -49.6% | -29.1% | -26.8% | -41.3% | -36.6% | +17.6% | +27.6% | +24.1% | +42.1% | +2.8% | -17.6% | +1.2% | -18.6% | -35.3% | |
| Quick Ratio | 1.08 | 0.76 | 1.05 | 1.08 | 0.98 | 0.94 | 1.28 | 1.64 | 2.93 | 3.56 | 2.99 | 3.32 | 4.19 | 4.88 | 5.11 | 5.25 | 3.54 | 3.82 | 4.11 | 3.68 | 3.45 |
| — | -18.5% | -18.1% | -34.5% | -66.4% | -73.7% | -57.3% | -50.5% | -30.1% | -27.1% | -41.5% | -36.7% | +18.5% | +27.8% | +24.4% | +42.5% | +2.5% | -17.6% | +1.0% | -19.0% | -35.9% | |
| Interest Coverage | -3.27 | -4.10 | -0.78 | -7.10 | -2.06 | -2.31 | -1.13 | -1.76 | -1.81 | 3.67 | -5.34 | -5.72 | -4.68 | -4.62 | -4.92 | -5.53 | -4.93 | -6.75 | -5.17 | 5.86 | -5.46 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KPTI stock.
Karyopharm Therapeutics Inc.'s current P/E is -0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Karyopharm Therapeutics Inc.'s current operating margin is -62.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Karyopharm Therapeutics Inc.'s business trajectory between earnings reports.